Impact of obesity on clinical outcomes of methicillin-susceptible bloodstream infections.

Obesity affects over one-third of U.S. adults and complicates the treatment of methicillin-susceptible (MSSA) bloodstream infections (BSI). A study at the University of Florida Health Centers compared clinical outcomes between 233 obese and non-obese patients receiving cefazolin for MSSA BSI. No significant differences were found in clinical success (81.9% vs 82.7%), mortality (7.2% vs 5.3%), or adverse events (3.6% vs 3.3%). However, obese patients took longer to clear blood cultures (4.62 vs 4.01 days, = 0.017).